ArticleScientific reports2021

ISL1 promotes enzalutamide resistance in castration-resistant prostate cancer (CRPC) through epithelial to mesenchymal transition (EMT).

Jae Duck Choi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.